Clinical trials: SARS-CoV-2 Infection
Cytokine Storm (Covid-19)
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years…
- Trial name
- RUXCOVID (NCT04362137)
- Testing
- Ruxolitinib
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Coronavirus Disease 2019 (COVID-19)
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC)…
- Trial name
- NCT04409509
- Testing
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
- Where
- 14 sites in United States
- Volunteers
- 124 people
- Sponsor
- CSL Behring
Hypertension, COVID-19
ARB, ACEi, DRi Effects on COVID-19 Course Disease
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2.
- Trial name
- BIRCOV (NCT04364984)
- Testing
- Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, Direct renin inhibitor
- Where
- Ukraine
- Volunteers
- 112 people
- Sponsor
- Medical Practice Prof D. Ivanov
SARS-CoV-2 Acute Respiratory Disease, Covid19
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
During this pandemic period, the goal of the health care system is to optimize the use of intensive care services for patients infected with SARS-CoV-2, given the frequency of complications that can lead to high mortality.
- Trial name
- STC-19 (NCT04371471)
- Testing
- STC-19 score
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
COVID-19, Cardiorespiratory Failure
Lift Mobile Mindfulness for COVID-19 Distress Symptoms
This is a randomized clinical trial (RCT) nested within the NIH PETAL Network's COVID cohort study (BLUE CORAL [Biology and Longitudinal Epidemiology: COVID Observational Study]) of patients hospitalized for COVID-19-related…
- Trial name
- LIFTCOVID (NCT04581200)
- Testing
- Lift
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Duke University
COVID-19
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
At present there is no approved drug treatment for Covid-19. In this study we plan to investigate if an experimental drug called IMU-838 (vidofludimus calcium) can improve your symptoms, prevent worsening that would initiate…
- Trial name
- NCT04379271
- Testing
- IMU-838
- Where
- 4 sites in Bulgaria, Germany
- Volunteers
- 234 people
- Sponsor
- Immunic AG
Sars-CoV2
Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19
The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04411667
- Testing
- Octagam
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- George Sakoulas, MD
COVID-19
Vale+ Tu Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID-19
The purpose of this study is to adapt and pilot test the feasibility of implementing a corner-based risk reduction program that aims to assist Latino day laborers (LDL) in their efforts to adhere to COVID-19 mitigation practices…
- Trial name
- NCT05248399
- Testing
- COVID-19 Group Problem Solving, Standard of Care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The University of Texas Health Science Center, Houston
COVID-19
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.
- Trial name
- APN01-COVID-19 (NCT04335136)
- Testing
- RhACE2 APN01, Physiological saline solution
- Where
- 22 sites in Austria, Denmark and 3 more
- Volunteers
- 185 people
- Sponsor
- Apeiron Biologics
Depressive Symptoms
Brief Video Interventions for Depression
In this study, we test brief video interventions for those with elevated depressive symptoms. We randomize participants to one of three conditions.
- Trial name
- NCT04643964
- Testing
- Entrée: Cognitive skills, Entrée: Behavioral skills, Entrée: Interpersonal skills
- Where
- United States
- Volunteers
- 655 people
- Sponsor
- Ohio State University
COVID-19
Dapagliflozin in Respiratory Failure in Patients With COVID-19
This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with coronavirus disease 2019 (COVID-19) in the United States, Brazil, Mexico, Argentina…
- Trial name
- DARE-19 (NCT04350593)
- Testing
- Dapagliflozin 10 milligram (mg)
- Where
- 95 sites in United States, Argentina and 5 more
- Volunteers
- 1,250 people
- Sponsor
- Saint Luke's Health System
COVID-19
Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
The purpose of this study is to compare COVID-19 knowledge, experiences, and health behaviors between participants who received the health initiative and those who did not.
- Trial name
- NCT06938230
- Testing
- Health Education Initiative
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Miami
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 To evaluate the clinical efficacy of…
- Trial name
- NCT04426695
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 123 sites in United States, Brazil and 4 more
- Volunteers
- 2,252 people
- Sponsor
- Regeneron Pharmaceuticals
2019 Novel Coronavirus Infection, COVID-19 Virus Infection
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.
- Conditions
- 2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection
- Trial name
- NCT04778059
- Testing
- USB002
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- US Biotest, Inc.
COVID-19, COVID
Pegylated Interferon Lambda Treatment for COVID-19
Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.
- Trial name
- NCT04343976
- Testing
- Pegylated interferon lambda
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Raymond Chung
Covid19
Dietary Supplements for COVID-19
This is a double blind, placebo controlled, phase III randomized controlled trial evaluating the effects of the dietary supplements vitamin C, vitamin D, vitamin K, and zinc versus placebo on the overall health, symptom severity…
- Trial name
- NCT04780061
- Testing
- Vitamin D3 50,000 IU, Vitamin C/Zinc, Vitamin K2/D
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- The Canadian College of Naturopathic Medicine
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Kidney Transplant Recipient
Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients
The purpose of this research is to see if a dose of the Janssen Ad26.CoV2.S vaccine effects the immune protection in individuals who have had a kidney transplant and two or three doses of mRNA vaccine (Pfizer and/or Moderna…
- Trial name
- NCT05220397
- Testing
- Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
- Where
- 3 sites in United States
- Volunteers
- 468 people
- Sponsor
- Mark Stegall
SARS-CoV-2, COVID-19
Stopping ACE-inhibitors in COVID-19
ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor blockers (ARB) improves outcomes in symptomatic…
- Trial name
- ACEI-COVID (NCT04353596)
- Testing
- ACE inhibitor, angiotensin receptor blocker
- Where
- 31 sites in Austria, Germany
- Volunteers
- 216 people
- Sponsor
- Medical University Innsbruck
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.